<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04899115</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00194437</org_study_id>
    <nct_id>NCT04899115</nct_id>
  </id_info>
  <brief_title>VE303 for Treatment of Hepatic Encephalopathy (HE)</brief_title>
  <official_title>A Randomized Controlled Trial of VE303 to Treat Hepatic Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Patricia Bloom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vedanta Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>American College of Gastroenterology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Association for the Study of Liver Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is studying the use of a new drug to learn about its safety and efficacy as a&#xD;
      treatment for hepatic encephalopathy.&#xD;
&#xD;
      Eligible participants will be enrolled and given oral antibiotics followed by 14 days of the&#xD;
      study drug (placebo vs.VE303). There will be visits as well as other procedures to collect&#xD;
      blood and stool samples, and have tests of your cognition (thinking) for this research study.&#xD;
&#xD;
      The hypothesis is that VE303 will safely and effectively improve cognitive function in&#xD;
      patients with a history of overt hepatic encephalopathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized 2:1 to VE303 vs placebo. There will be no stratification.&#xD;
After the trial enrolls the first 9 patients, an interim analysis to evaluate safety of VE303 in this population will take place. If there is no concern for a higher rate of Serious adverse events (SAEs) in the VE303 group, enrollment will continue to reach a total of 18 patients.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Study staff will remain blinded to subject randomization until the study period is over.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of serious adverse events up to week 6</measure>
    <time_frame>Week 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Psychometric Hepatic Encephalopathy Score (PHES) as a measure of cognitive function from pre-vancomycin to week 6</measure>
    <time_frame>baseline (pre-vancomycin), Week 6</time_frame>
    <description>This score is a battery of 5 paper-pencil tests that evaluate cognitive and psychomotor processing speed and visuomotor coordination. Scores on each subtest are assigned values based on age-related norms (1+ for scores better than 1 standard deviation (SD) above the normal mean to -3 for scores more than 3 SDs below the normal mean). Combined scores vary from +6 to -18.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalizations for overt hepatic encephalopathy (OHE) up to week 26</measure>
    <time_frame>up to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events up to week 26</measure>
    <time_frame>up to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Reported Outcome Measurement Information System (PROMIS) Global Health reported from pre-vancomycin to week 26</measure>
    <time_frame>baseline (pre-vancomycin), week 26</time_frame>
    <description>The PROMIS v 1.1 is a 10 question scale where participants select answers from (0) up to (10). Higher scores indicate better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to overt HE</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in microbiome composition from pre-vancomycin to week 26</measure>
    <time_frame>baseline (pre-vancomycin), week 26</time_frame>
    <description>This will be calculated by beta diversity between stool collection timepoints and will have metagenomic sequencing on stool to assess this.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum and stool biomarkers from pre-vancomycin to week 26</measure>
    <time_frame>baseline (pre-vancomycin), week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PHES from pre-vancomycin to week 26</measure>
    <time_frame>pre-vancomycin up to week 26</time_frame>
    <description>This score is a battery of 5 paper-pencil tests that evaluate cognitive and psychomotor processing speed and visuomotor coordination. Scores on each subtest are assigned values based on age-related norms (1+ for scores better than 1 standard deviation (SD) above the normal mean to -3 for scores more than 3 SDs below the normal mean). Combined scores vary from +6 to -18.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VE303</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VE303 is a live biotherapeutic product comprising 8 nonpathogenic commensal strains of Clostridia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of placebo for 14 days taken once daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VE303</intervention_name>
    <description>Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of VE303 taken daily for 14 days.&#xD;
The quantity of each strain is proportioned to assure a specific per-strain per-capsule titer. The 8 strains are blended together with a micro-crystalline cellulose flow agent and placed in enteric capsules.</description>
    <arm_group_label>VE303</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral vancomycin</intervention_name>
    <description>All enrolled subjects will receive 5 days of oral vancomycin 125 mg four times a day (q.i.d).</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>VE303</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of cirrhosis based on liver biopsy, imaging, or evidence of clinical&#xD;
             decompensation&#xD;
&#xD;
          -  History of at least one episode of overt HE any time in the past&#xD;
&#xD;
          -  Prescribed both lactulose and rifaximin, and compliant with this treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current episode of overt HE&#xD;
&#xD;
          -  Variceal bleeding in the last 4 weeks&#xD;
&#xD;
          -  Gut-absorbable or intravenous antibiotic therapy in the last 28 days&#xD;
&#xD;
          -  Fecal microbiota transplant in the last 6 months&#xD;
&#xD;
          -  Use of probiotics in the last 2 weeks&#xD;
&#xD;
          -  Alcohol or illicit drug intake in the last 4 weeks&#xD;
&#xD;
          -  Primary sclerosing cholangitis as etiology of liver disease&#xD;
&#xD;
          -  History of inflammatory bowel disease, short gut, gastrointestinal tract fistulas,&#xD;
             intestinal ischemia, or any form of ongoing colitis&#xD;
&#xD;
          -  Prior diagnosis of dementia or other primary neurocognitive disorder&#xD;
&#xD;
          -  Known hypersensitivity/allergy/intolerance to Vancomycin and any ingredients of VE303:&#xD;
             sucrose, histidine, yeast extract, cysteine, metabisulfite, and microcrystalline&#xD;
             cellulose&#xD;
&#xD;
          -  History of Roux-en-Y Gastric bypass&#xD;
&#xD;
          -  Any gastrointestinal surgery in the last year&#xD;
&#xD;
          -  Substantial immune compromise/deficiency (e.g., uncontrolled human immunodeficiency&#xD;
             virus, active immune suppressive therapy including high doses of corticosteroids or&#xD;
             medications to prevent graft rejection, recent myeloablative therapy, sustained&#xD;
             neutropenia)&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Model for end-stage liver disease (MELD) &gt; 20&#xD;
&#xD;
          -  History of spontaneous bacterial peritonitis&#xD;
&#xD;
          -  Hemodialysis in the last 28 days&#xD;
&#xD;
          -  Placement of a portosystemic shunt or transjugular intrahepatic portosystemic shunt in&#xD;
             the last 3 months (permissible if placed &gt;3 months before enrollment)&#xD;
&#xD;
          -  Unstable doses of opiates, benzodiazepines or other sedating medication&#xD;
&#xD;
          -  Chronic methadone or low dose benzodiazepines (for example) is acceptable&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Bloom, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haila Asefa</last_name>
    <phone>734-232-0284</phone>
    <email>asefah@med.umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia Bloom, MD</last_name>
    <phone>734-647-9252</phone>
    <email>ppbloom@umich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haila Asefa</last_name>
      <phone>734-232-0284</phone>
      <email>asefah@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Patricia Bloom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Patricia Bloom</investigator_full_name>
    <investigator_title>Clinical Lecturer in Internal Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

